Download PDFPDF
Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Reply to the letter of Dr. Tarannum Mansoori
    • Wungrak Choi, Doctor of Ophthalmology Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
    • Other Contributors:
      • Chan Yun Kim, Doctor of Ophthalmology
      • Gong Je Seong, Doctor of Ophthalmology
      • Min Kim, Doctor of Ophthalmology

    We would like to thank Dr. Tarannum Mansoori for the interest in our study, “Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients” and highlighting important issues about the intraocular pressure (IOP) measurement methods and the correlation of IOP with age.1
    We used KT-800 Non-Contact Tonometer (Kowa, Tokyo, Japan) to measure IOP initially and rechecked with GAT if necessary. Unless the patient was diagnosed with glaucoma, NCT was initially used to measure both pre- and post-injection IOP.
    As Dr. Tarannum Mansoori has pointed out, we also agree that GAT is the gold standard for IOP measurement. If the IOP measured with NCT was found to be high, it was always rechecked with GAT. GAT was used in 2 situations in our study. First, when the patients had a previous history of glaucoma, and second, when the patients’ IOP as measured with NCT was high (greater than 20). Thus, in cases of high IOP, the measurement involved NCT and was also always double checked with GAT. Moreover, multiple IOP measurements were obtained with GAT in cases of high IOP, and the average value of the measurements was regarded as the final IOP.
    The range of age of the patients for injection of intravitreal dexamethasone was broad, from 16 to 88 years. We know that very young age (less than six years) or an older age are risk factors for steroid-induced glaucoma.2 However, regrettably, we have not performed any further analysis...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant

    I read with interest and appreciate the article by Choi et al 1 on 'Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients'.
    As the study looks at the IOP changes after intravitreal dexamethasone implant, how the IOP was recorded for the patients is very important. The authors have reported that the intraocular pressure (IOP) was measured by non-contact tonometer (NCT) or Goldmann applanation tonometry (GAT) in this study. First, it is not mentioned as to which NCT was used for IOP measurement. If NCT was used to measure pre-injection IOP, was it used to measure post-injection IOP measurement also? Or on different visits IOP recording was done with NCT or GAT, is not clear. As GAT is still considered as a gold standard for IOP measurement, if IOP on NCT is found to be high, ideally it should be rechecked with GAT. Second, it is not mentioned whether a single IOP measurement was taken or multiple IOP measurements were obtained, taking the average value as the final IOP. Third, a s the lower range of age was 16 years (Table 1), was there any correlation of IOP change after the injection with the age?


    1. Choi W, Park SE, Kang HG et al. Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients. Br J Ophthalmol 2018. Epub ahead
    of print. doi:10.1136/ bjophthalmol-2018-312958

    Conflict of Interest:
    None declared.